Bristol Myers Squibb plans to release initial late-stage trial data on Cobenfy in Alzheimer's-related psychosis during the ...

Each night, our brains execute a "wash and rinse" routine that clears away harmful protein waste linked to neurodegenerative ...

Fact checked by Nick Blackmer Zunveyl (benzgalantamine)—a better-tolerated version of the Alzheimer’s drug Razadyne ...

A new pill that ‘slows down Alzheimer's ' is being considered for use in the NHS. Developed by a small British firm in ...

As the second oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better safety ...

It raises the prospect of it being the third successive drug in a new era of Alzheimer’s treatments to not be approved for NHS patients amid concerns that Nice’s cost assessments of the ...

The European Medicines Agency has said no to approving a new drug for Alzheimer's disease in the EU. Aducanumab does not appear to be effective at treating adults with early-stage symptoms ...

Bristol Myers Squibb (NYSE:BMY) believes Alzheimer’s is the largest market for its newly approved schizophrenia drug, Cobenfy, which it expects to eventually generate billions of dollars in revenue.

The federal Food & Drug Administration has approved two new Alzheimer’s medications that can offer people more time to live normally, but accessing them in Florida is complicated. Hold-ups ...

The study also integrates drug databases ... Women With Ovarian Removal Have Unique Risk and Resilience Factors for Alzheimer Disease Dec. 5, 2024 — New research has found that women who have ...